Keywords: درمانی درمان بیماری; Neuroscience; Longitudinal cohort; Alzheimer's disease; Disease-modifying therapy; Parkinson's disease; clinical trials;
مقالات ISI درمانی درمان بیماری (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: درمانی درمان بیماری; disease-modifying therapy; multiple sclerosis; orally administered MS treatments; self-injectables; treatment journey; treatment patterns;
Keywords: درمانی درمان بیماری; Quality of life; Patient care management; Patient reported outcomes; EQ5D; Registries; Regression analysis; AIC; Aikake's Information Criterion; CIS; Clinically Isolated Syndrome; DMT; Disease-modifying Therapy; EDSS; Expanded Disability Status Scale; EQ-
Keywords: درمانی درمان بیماری; AML; acute myeloid leukemia; CI; confidence interval; CPT; Current Procedural Terminology; DMT; disease-modifying therapy; ESA; erythropoiesis-stimulating agent; FDA; Food and Drug Administration; HCPCS; Healthcare Common Procedure Coding System; HMA; hyp
Keywords: درمانی درمان بیماری; Multiple sclerosis; Disease-modifying therapy; Adherence; Utilization; Costs;
Keywords: درمانی درمان بیماری; AHSCT; autologous hematopoietic stem cell transplant; ARR; annualized relapse rate; BVL; brain volume loss; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; GA; glatiramer acetate; HRQoL; health-related quality of life; IFN; interfe
Keywords: درمانی درمان بیماری; Alemtuzumab; Disability; Disease-modifying therapy; Expanded Disability Status Scale; Functional systems; Multiple sclerosis;
Keywords: درمانی درمان بیماری; Network meta-analysis; Systematic review; Disease-modifying therapy; Multiple sclerosis; Disability progression; Relapse;
Keywords: درمانی درمان بیماری; Diagnosis; Outcome; Disease-modifying therapy; Treatment switch; Treatment escalation;
Keywords: درمانی درمان بیماری; Multiple sclerosis; Exacerbation; Corticosteroids; Adrenocorticotrophic hormone; Disease-modifying therapy; MS; Pregnancy;
Keywords: درمانی درمان بیماری; AAN; American Academy of Neurology; ABN; Association of British Neurologists; AUD; Australian dollars; CIS; clinically isolated syndrome; CNS; central nervous system; DMT; disease-modifying therapy; EDSS; Kurtzke Expanded Disability Status Scale; EMA; Eur
Keywords: درمانی درمان بیماری; Alzheimer's disease; Mild cognitive impairment; Cerebrospinal fluid; Plasma; Biomarkers; Immunoassay; ADNI; Disease-modifying therapy; Aβ1-42; Tau;
Keywords: درمانی درمان بیماری; BBB; blood-brain barrier; CNS; central nervous system; DMF; dimethyl fumarate; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; FDA; Food and Drug Administration; GA; glatiramer acetate; JCV; John Cunningham virus; MRI; magnetic res
Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week
Keywords: درمانی درمان بیماری; AE; adverse event; ARR; annualized relapse rate; CDW; confirmed disability worsening; CI; confidence interval; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; IFN; interferon; IM; intramuscular; IPD; individual patient data; NEDA;
Validation of an algorithm to detect severe MS relapses in administrative health databases
Keywords: درمانی درمان بیماری; Multiple sclerosis; Disease-modifying therapy; Relapse; Database; Epidemiology;
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
Keywords: درمانی درمان بیماری; Disability worsening; Natalizumab; Relapsing-remitting multiple sclerosis; EDSS milestones; CP; cumulative probability; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; RRMS; relapsing-remitting multiple sclerosis; SPMS; secondary p
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)
Keywords: درمانی درمان بیماری; AE; adverse event; ARR; annualized relapse rate; DMF; dimethyl fumarate; DMT; disease-modifying therapy; HR; hazard ratio; IPTW; inverse probability of treatment weight; JCV; John Cunningham virus; MS; multiple sclerosis; PML; progressive multifocal leuko
Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Keywords: درمانی درمان بیماری; Relapsing-remitting multiple sclerosis; High-risk multiple sclerosis; Disease-modifying therapy; High-efficacy disease-modifying therapy;
Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study
Keywords: درمانی درمان بیماری; AEs; adverse events; ALT; alanine aminotransferase; BL; baseline; CI; confidence interval; DMF; dimethyl fumarate; DMTs; disease-modifying therapies; EDSS; Expanded Disability Status Scale; ES; effect size; MedDRA; Medical Dictionary for Regulatory Activi
Cytokines and Disability in Interferon-β-1b Treated and Untreated Women with Multiple Sclerosis
Keywords: درمانی درمان بیماری; Disease-modifying therapy; Expanded Disability Status Scale; TNF-α; IFN-γ; IL-4; IL-10
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
Keywords: درمانی درمان بیماری; Disease-modifying therapy; Fingolimod; Interferon; Multiple sclerosis; Sphingosine 1-phosphate receptor modulator; Relapse rate;
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study
Keywords: درمانی درمان بیماری; Disease-modifying therapy; Fingolimod; Multiple sclerosis; Sphingosine 1-phosphate receptor modulator; Treatment history; Relapse rate;
Migraine and multiple sclerosis: Epidemiology and approach to treatment
Keywords: درمانی درمان بیماری; Migraine; Multiple sclerosis; Epidemiology; Headache; Disease-modifying therapy; Neuroimaging
The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis
Keywords: درمانی درمان بیماری; Multiple sclerosis; Drug safety; Pharmacogenomics; Disease-modifying therapy; Genetics; Drug toxicity
Tratamiento de fondo del sÃndrome seco. ¿Qué puede aportar el reumatólogo?
Keywords: درمانی درمان بیماری; SÃndrome de Sjogren primario; Tratamiento de fondo; Tratamiento biológico; Primary Sjögren syndrome; Disease-modifying therapy; Biologic therapy;
Mitoxantrone for worsening multiple sclerosis: Tolerability, toxicity, adherence and efficacy in the clinical setting
Keywords: درمانی درمان بیماری; Multiple sclerosis; Mitoxantrone; Immunosuppression; Disease-modifying therapy; Clinical neurology
The implications of immunogenicity for protein-based multiple sclerosis therapies
Keywords: درمانی درمان بیماری; Binding antibodies; Disease-modifying therapy; Glatiramer acetate; Interferon beta-1a; Interferon beta-1b; Multiple sclerosis; Natalizumab; Neutralizing antibodies
Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy
Keywords: درمانی درمان بیماری; Multiple sclerosis; Disease-modifying therapy; Interferon beta; Neurotrophins; Brain-derived neurotrophic factor; Nerve growth factor; Glial cell line-derived neurotrophic factor; Neurotrophin 3; Neurotrophin 4/5; Neuroprotection
Cognitive evaluation of disease-modifying efficacy of Galantamine and Memantine in the APP23 model
Keywords: درمانی درمان بیماری; APP23 transgenic mouse model; Alzheimer's disease; Cognition; Galantamine; Memantine; Disease-modifying therapy